WORLD TRADE
G/TBT/N/SWE/52
7 July 2005
ORGANIZATION
(05-3011)
Committee on Technical Barriers to Trade
Original: English
NOTIFICATION
The following notification is being circulated in accordance with Article 10.6.
1.
Member to Agreement notifying: SWEDEN
If applicable, name of local government involved (Articles 3.2 and 7.2):
2.
Agency responsible: The Medical Product Agency
Name and address (including telephone and fax numbers, e-mail and web-site
addresses, if available) of agency or authority designated to handle comments
regarding the notification shall be indicated if different from above:
Kommerskollegium (National Board of Trade)
Box 6803, S-113 86
STOCKHOLM
Telephone:
fax
(+46) 8 690 48 00
(+46) 8 690 48 40
E-mail:
Website:
registrator@kommers.se
www.kommers.se
3.
Notified under Article 2.9.2 [ X ], 2.10.1 [ ], 5.6.2 [ ], 5.7.1 [ ], other:
4.
Products covered (HS or CCCN where applicable, otherwise national tariff heading.
ICS numbers may be provided in addition, where applicable): GBL and 1,4-butanediol
5.
Title, number of pages and language(s) of the notified document: The Medical Products
Agency's administrative provisions on exemption from the requirement for a licence under
the Act (1999:42) banning certain substances that are harmful to health (LVFS 2005:x)
(2 pages, in Swedish)
6.
Description of content: Sweden intends to classify GBL and 1,4 butanediol as products
harmful to health (see notification G/TBT/N/SWE/47 and G/TBT/N/SWE/48), which will
mean, inter alia, that the substances may not be imported or held without a special licence
issued by the Medical Products Agency or without the Medical Products Agency issuing
administrative provisions on exemption from the requirement for a licence. A licence may
be granted for scientific or industrial purposes. In accordance with the draft, an exemption
is granted from the requirement for a licence contained in the Act on products harmful to
health for GBL or 1,4-BD that has been denatured and in connection with the manufacture
of a particular product containing GBL and/or 1,4-BD where there is no risk of the abuse of
the product.
. /.
G/TBT/N/SWE/52
Page 2
7.
Objective and rationale, including the nature of urgent problems where applicable:
GBL and 1,4 butanediol are used fairly extensively in industry, which means there is an
increased need for a system which does not hinder the use of these products, while at the
same time minimising the risk of these substances being abused.
8.
Relevant documents: -
9.
Proposed date of adoption:
1 October 2005
Proposed date of entry into force:
1 November 2005
10.
Final date for comments: 14 September 2005
11.
Texts available from: National enquiry point [ X ] or address, telephone and fax
numbers, e-mail and web-site addresses, if available of the other body: